NASDAQ:GMDA - Gamida Cell Stock Price, Forecast & News

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

Gamida Cell Ltd (NASDAQ:GMDA) announced its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.07. View Gamida Cell's Earnings History.

Gamida Cell is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Gamida Cell.

3 Wall Street analysts have issued 12 month price objectives for Gamida Cell's stock. Their forecasts range from $16.00 to $19.00. On average, they expect Gamida Cell's stock price to reach $17.67 in the next twelve months. This suggests a possible upside of 270.4% from the stock's current price. View Analyst Price Targets for Gamida Cell.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gamida Cell.

Media stories about GMDA stock have trended positive on Friday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Gamida Cell earned a news sentiment score of 2.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Gamida Cell.

Gamida Cell saw a increase in short interest in November. As of November 29th, there was short interest totalling 44,100 shares, an increase of 12.2% from the November 14th total of 39,300 shares. Based on an average trading volume of 36,400 shares, the days-to-cover ratio is currently 1.2 days. Approximately 0.4% of the company's stock are sold short. View Gamida Cell's Current Options Chain.

Some companies that are related to Gamida Cell include Harpoon Therapeutics (HARP), Gritstone Oncology (GRTS), BioCryst Pharmaceuticals (BCRX), Tcr2 Therapeutics (TCRR), PDL BioPharma (PDLI), Oyster Point Pharma (OYST), Cellular Biomedicine Group (CBMG), Eiger Biopharmaceuticals (EIGR), Jounce Therapeutics (JNCE), CASI Pharmaceuticals (CASI), Compugen (CGEN), Scholar Rock (SRRK), ADMA Biologics (ADMA), Aptose Biosciences (APTO) and Sutro Biopharma (STRO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Palatin Technologies (PTN), Celgene (CELG), Cisco Systems (CSCO), LYFT (LYFT), Outlook Therapeutics (OTLK), Ovid Therapeutics (OVID), PhaseBio Pharmaceuticals (PHAS), Spring Bank Pharmaceuticals (SBPH), AcelRx Pharmaceuticals (ACRX) and Antares Pharma (ATRS).

(GMDA) raised $50 million in an initial public offering (IPO) on Friday, October 26th 2018. The company issued 3,600,000 shares at $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

Gamida Cell's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (0.29%) and Phoenix Holdings Ltd. (0.12%).

GMDA stock was bought by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd. and Millennium Management LLC.

Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GMDA stock can currently be purchased for approximately $4.77.

Gamida Cell has a market capitalization of $115.53 million. The company earns $-52,930,000.00 in net income (profit) each year or ($10.53) on an earnings per share basis. Gamida Cell employs 70 workers across the globe.View Additional Information About Gamida Cell.

The official website for Gamida Cell is http://www.gamida-cell.com/.

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company can be reached via phone at 972-2659-5666 or via email at [email protected]